Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index

[1]  J. Brenton,et al.  Evolution of platinum resistance in high-grade serous ovarian cancer. , 2011, The Lancet. Oncology.

[2]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[3]  K. Matsuo,et al.  Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas , 2010, Archives of Gynecology and Obstetrics.

[4]  D. Alberts,et al.  Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study , 2010, Oncology.

[5]  F. Heitz,et al.  Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs , 2010, Expert review of anticancer therapy.

[6]  H. Chung,et al.  In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study , 2009, Journal of Cancer Research and Clinical Oncology.

[7]  I. Cree.  Chemosensitivity and chemoresistance testing in ovarian cancer , 2009, Current opinion in obstetrics & gynecology.

[8]  J. McAlpine,et al.  Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. , 2008, Gynecologic oncology.

[9]  T. Fehm,et al.  Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. , 2008, Anticancer research.

[10]  I. Cree,et al.  A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer , 2007, Anti-cancer drugs.

[11]  B. Monk,et al.  Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. , 2005, Gynecologic oncology.

[12]  I. Cree,et al.  A prospective randomized controlled trial of ATP-based tumor chemosensitivity assay (ATP-TCA) directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer , 2005 .

[13]  P. Disaia,et al.  Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. , 2003, American journal of obstetrics and gynecology.

[14]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[15]  I. Cree,et al.  Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma , 2003, BMC Cancer.

[16]  C. McLaren,et al.  Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. , 2002, Gynecologic oncology.

[17]  R. Mirhashemi,et al.  Management of recurrent ovarian cancer: evidence-based decisions. , 2002, Current opinion in oncology.

[18]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis , 2002 .

[19]  I. Cree,et al.  Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. , 2000, Gynecologic oncology.

[20]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[21]  M. Bookman,et al.  Second-line treatment of ovarian cancer. , 2000, The oncologist.

[22]  I. Cree,et al.  Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. , 1995, Cancer research.

[23]  J. Thigpen,et al.  Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Pettersen,et al.  Flow cytometric DNA ploidy and S‐phase heterogeneity in advanced ovarian carcinoma , 1994, Cancer.

[25]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[26]  D. Morton,et al.  Heterogeneity of human metastatic clones by in vitro chemosensitivity testing. Implications for the clinical application of the clonogenic assay. , 1983, Archives of surgery.

[27]  V. Gebski,et al.  A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.